Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors (ENGAGE)

11 november 2026 bijgewerkt door: Frontier Medicines Corporation

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of FMC-242 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

The goal of this clinical trial is to learn if treatment in adults with select solid tumors with FMC-242 alone and in combinations with other cancer drugs is safe and effective. The main questions it aims to answer are:

Is treatment with FMC-242 alone safe and tolerable and at what dose? Is treatment with FMC-242 combined other cancer drugs safe and tolerable and at what doses?

Participants will need to come to the clinic to have the following:

  • Physical exams to see if there are any side effects
  • Standard lab tests to observe blood counts and other values
  • ECGs to measure heart signals
  • Blood drawn to measure how the drugs are being metabolized
  • Imaging such as CT scans to monitor if the cancer is growing or not

Studie Overzicht

Gedetailleerde beschrijving

This is a first-in-human, Phase 1/2, open-label, multi-center dose escalation and expansion study to evaluate the safety, tolerability, PK, and anti-tumor activity of FMC-242 monotherapy and in combination in participants with locally advanced or metastatic solid tumors. FMC-242 is in a new class of drugs called PI3Kα:RAS breakers. The combination escalation cohorts may enroll while the monotherapy portion is still determining MTD/recommended dose for expansion (RDE).

This study is being conducted in two phases:

Phase 1 Dose Escalation: to determine the MTD and/or preliminary RP2D(s) and dosing regimen of FMC-242 monotherapy and in combination.

Phase 2 Cohort Expansion: to evaluate the efficacy and safety of FMC-242 at the RP2D(s) as a monotherapy and in combination in disease-specific cohorts.

After consenting to participate, participants will complete screening assessments during a Screening Period. Eligible participants will receive FMC-242 orally, at approximately the same time each day.

Depending on the tumor type, participants in combination cohorts will also receive the addition of another cancer drug administered per the local prescribing information/investigational labeling.

Studietype

Ingrijpend

Inschrijving (Geschat)

282

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Males and females of age ≥ 18 years at the time of signing the informed consent document.
  • No known downstream mutations in the AKT or RAS pathway
  • Measurable disease per RECIST v1.1.
  • Documented disease progression on, or disease recurrence after at least 1 line of standard of care (SoC) systemic treatment, including approved targeted therapy for patients with actionable mutations, or, in the opinion of the Investigator, would not be able to tolerate SoC therapy, or refused SoC therapy.
  • Eastern Cooperative Oncology Group performance status 0-1.
  • Adequate hematological, renal, and hepatic function.
  • In Phase 1 only, must be willing to provide an on treatment tumor biopsy provided it is safe and medically feasible.
  • Women and men of child-bearing potential must agree to use highly effective contraceptive methods.
  • Willing and able to adhere to the study visit schedule and other protocol requirements.
  • Has an archival tissue for retrospective confirmatory testing, unless discussed with the study Medical Monitor.

Exclusion Criteria:

  • Prior use of a PI3Kα:RAS breaker (e.g., BBO-10203, VVD-159642).
  • Prior use of a RAS inhibitor (either pan-RASi or isoform-specific)
  • Received any systemic anti-cancer therapy or investigational therapy within 21 days or 5 half-lives, whichever is shorter, prior to the first dose of study drug.
  • Received radiation within 14 days prior to the first dose of study drug.
  • Clinically significant toxicity resulting from prior cancer therapies that have not returned to baseline or ≤ Grade 1
  • Known, uncontrolled central nervous system (CNS) metastases.
  • History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease
  • Prior malignancy, requiring treatment or intervention, within the previous 3 years of study drug dosing, except for appropriately treated local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, which are allowed.
  • Pregnant or breastfeeding.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: FMC-242 Monotherapy

FMC-242 alone

PI3Kα:RAS breaker

Experimenteel: Combination Cohort A

FMC-242 in combination with trastuzumab

PI3Kα:RAS breaker

HER2 targeting agent

Andere namen:
  • Herceptin
Experimenteel: Combination Cohort B

FMC-242 in combination with fulvestrant

PI3Kα:RAS breaker

selective estrogen receptor degrader

Andere namen:
  • Faslodex
Experimenteel: Combination Cohort C

FMC-242 in combination with a Pan (K)RAS inhibitor

PI3Kα:RAS breaker

Pan (K)RAS inhibitor

Experimenteel: Combination Cohort D

FMC-242 in combination with FMC-376

PI3Kα:RAS breaker

KRAS G12C inhibitor (experimental)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 1 and Phase 2: Adverse Events
Tijdsspanne: Approximately 24 months

Number and grade of adverse events (AEs) with FMC-242 alone and in each of the combinations using CTCAE v 6.0

Approximately 24 months
Phase 1 : Dose Limiting Toxicities
Tijdsspanne: Up to 21 or 28 days

Number of dose limiting toxicities (DLTs) with FMC-242 alone and in each of the combinations

Up to 21 or 28 days
Phase 2: Overall Response Rate
Tijdsspanne: Approximately 24 months

Assess the overall response rate (ORR) using RECIST 1.1 in participants treated with FMC-242 alone and in each of the combinations

Approximately 24 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 1: Assess anti-tumor activity
Tijdsspanne: Approximately 24 months

To assess preliminary anti-tumor activity of FMC-242 alone and in combinations using RECIST v1.1

Approximately 24 months
Phase 1: FMC-242 Maximum observed plasma concentration
Tijdsspanne: 6 weeks

Measure the maximum observed plasma concentration (Cmax) for FMC-242

6 weeks
Phase 1: FMC-242 time to maximum observed plasma concentration
Tijdsspanne: 6 weeks

Measure time to maximum observed plasma concentration (Tmax) for FMC-242

6 weeks
Phase 1: FMC-242 trough observed concentration
Tijdsspanne: 6 weeks

Measure trough observed concentration (Cmin) for FMC-242

6 weeks
Phase 1: Area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval
Tijdsspanne: 6 weeks

Measure area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval (AUC0-t, AUCtau) for FMC-242

6 weeks
Phase 1: Terminal half-life
Tijdsspanne: 6 weeks

Measure the terminal half-life (t1/2) for FMC-242

6 weeks
Phase 1: Apparent clearance
Tijdsspanne: 6 weeks

Determine apparent the clearance (Cl/F) for FMC-242

6 weeks
Phase 1: Determine the volume of distribution
Tijdsspanne: 6 weeks

Determine volume of distribution (Vd/F) for FMC-242

6 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Aaron (Ron) Weitzman, MD, Frontier Medicines

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 januari 2029

Studie voltooiing (Geschat)

1 januari 2030

Studieregistratiedata

Eerst ingediend

11 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

11 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Aggregate study data will be shared at the end of the study.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren